

## Press Release

**Timo Lindemann**  
Corporate Communications

Fresenius SE & Co. KGaA  
Else-Kröner-Straße 1  
61352 Bad Homburg  
Germany  
T +49 6172 608 7939  
M +49 151 1551 5324  
[timo.lindemann@fresenius.com](mailto:timo.lindemann@fresenius.com)  
[www.fresenius.com](http://www.fresenius.com)

May 17, 2024

### **Resolutions of the Annual General Meeting of Fresenius SE & Co. KGaA**

At today's Annual General Meeting in Frankfurt am Main, the shareholders of Fresenius SE & Co. KGaA approved the proposals of the General Partner and the Supervisory Board by a large majority.

Wolfgang Kirsch, Chairman of the Supervisory Board, thanked the Management Board and emphasized Fresenius' strong performance in extremely challenging geopolitical times. "Against this backdrop, Fresenius has performed well as a leading healthcare company compared to the competition and has improved significantly in operational terms." He added that the #FutureFresenius program is strengthening Fresenius sustainably in the interests of all stakeholders. "The new Management Board team under the leadership of Michael Sen brings experience and complementary skills, team spirit and abilities, which will allow us to achieve the ambitious corporate goals and successfully implement #FutureFresenius," said Kirsch.

CEO Michael Sen thanked the shareholders for supporting the #FutureFresenius journey, as well as the members of the Supervisory Board and Chairman Wolfgang Kirsch for their excellent cooperation. "We have successfully completed the first phases of #FutureFresenius and regained trust. We shall now tackle the remaining phases with motivation and optimism," he stressed.

A large majority of 99.84% of shareholders voted in favor of approving the annual financial statements. The shareholders approved the Compensation Report for the 2023 fiscal year by 93.06%. Large majorities of 96.48% and 95.90% respectively approved the actions of the Management Board and the Supervisory Board in 2023.

At the Annual General Meeting of Fresenius SE & Co. KGaA, 72.65% of the registered capital was represented.

# # #

Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE) is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany. In the 2023 fiscal year, Fresenius generated €22.3 billion in annual revenue with its more than 190,000 employees. Fresenius offers solutions to the social challenges posed by a growing and aging population and the resulting need for affordable, high-quality healthcare. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as the investment company Fresenius Medical Care. With 140 hospitals and countless outpatient facilities, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 26 million patients every year. Fresenius Kabi's product portfolio includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and generic intravenous drugs. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952. She laid the foundations for a global enterprise that today pursues the goal of improving people's health. The largest shareholder is the non-profit Else Kröner-Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects.

For more information visit the company website at [www.fresenius.com](http://www.fresenius.com).  
Follow us on social media: [www.fresenius.com/socialmedia](http://www.fresenius.com/socialmedia)

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those currently expected due to various risk factors and uncertainties, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA  
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852  
Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE  
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673  
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Robert Möller, Dr. Michael Moser  
Chairman of the Supervisory Board: Wolfgang Kirsch